Propanc Biopharma targets February 2027 first-patient dosing for Phase 1b PRP cancer trial
Bitget2026/09/22 12:33- Propanc outlined new preclinical pancreatic cancer results for PRP, already presented in a newly released data package.
- Studies showed strong tumor control, fewer metastases, longer survival, and signs of improved response to standard chemotherapy.
- PRP uses a differentiation-based approach rather than RAS inhibition, positioning it as a potential complement to emerging RAS-targeted drugs.
- Next catalyst is a planned Phase 1b first-in-human trial in advanced solid tumors, with first patient dosing targeted for February 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Orient Precision Industries Holds Extraordinary Shareholders Meeting
Crypto prices
More
